UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to ____________ Commission File Number: 001-39122 89bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4946844 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 40 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |------------------------------------------------------------------------------------------|------------------------------------------| | For the transition period from ____ ...

| --- | --- | |-------|-------| | | | | | | | | | | | | | | | Disclaimer 1 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements concerning our plans, ob ...

Financial Performance - The company reported a net loss of $25.1 million for the three months ended June 30, 2022, compared to a net loss of $20.7 million for the same period in 2021, representing an increase of 16%[78]. - The company reported a total net loss before tax of $50.6 million for the six months ended June 30, 2022, compared to a net loss of $35.5 million for the same period in 2021, reflecting an increase of 42.5%[93]. - Net cash used in operating activities was $39.2 million for the six months ended June 30, 2022, compared to $35.1 million for the same period in 2021[108]. - The company expects to continue generating substantial operating losses as it expands research and development activities[105]. Research and Development - Research and development expenses increased by $4.1 million, or 26%, to $19.7 million for the three months ended June 30, 2022, primarily due to a $5.5 million increase in clinical development costs[88]. - Research and development expenses increased by $13.8 million, or 53%, to $39.5 million for the six months ended June 30, 2022, compared to $25.8 million for the same period in 2021[94]. - The company plans to initiate its Phase 3 SHTG trial in the first half of 2023, pending the end of Phase 2 meeting with the FDA[73]. - Pegozafermin demonstrated a 63% reduction in triglycerides in the highest dosing group during the Phase 2 trial, with statistically significant improvements in cardiovascular risk markers[73]. Operating Expenses - Total operating expenses for the six months ended June 30, 2022, were $49.8 million, an increase of $14.6 million compared to $35.3 million for the same period in 2021[93]. - General and administrative expenses increased by $0.1 million, or 3%, to $5.1 million for the three months ended June 30, 2022, primarily due to increased personnel-related costs[91]. - General and administrative expenses rose by $0.8 million, or 8%, to $10.3 million for the six months ended June 30, 2022, from $9.5 million in the prior year[95]. Cash Position and Funding - The company had cash and cash equivalents totaling $139.3 million as of June 30, 2022, which is expected to meet anticipated cash requirements for at least one year[76]. - As of June 30, 2022, the company had available cash and cash equivalents of $139.3 million and an accumulated deficit of $263.8 million[98]. - The company raised net proceeds of approximately $88.2 million from a public offering completed in July 2022[99]. - Net cash provided by investing activities was $19.2 million for the six months ended June 30, 2022, primarily from proceeds of $59.9 million from maturities of available-for-sale securities[111]. - Net cash provided by financing activities was $28.2 million for the six months ended June 30, 2022, mainly related to proceeds from a public offering[113]. - Future funding requirements will depend on the progress and costs of clinical trials and the ability to enroll patients in a timely manner[102]. Impact of External Factors - The ongoing COVID-19 pandemic has disrupted the company's business and may continue to delay its development timeline[79]. - The company is classified as a smaller reporting company under Rule 12b-2 of the Securities Exchange Act of 1934, thus not required to provide detailed market risk disclosures[122].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to ____________ Commission File Number: 001-39122 89bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4946844 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39122 | --- | --- | |------------------------------------------------------------------------------------------|--------------------- ...

| --- | --- | |-------|-------| | | | | | | | | | | | | | | | Disclaimer 1 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements concerning our plans, ob ...

| --- | --- | |-------|-------| | | | | | | | | | | | | | | | Disclaimer 1 Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements concerning our plans, ob ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to ____________ Commission File Number: 001-39122 89bio, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4946844 (Sta ...